Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Everolimus TFOS is a kinase inhibitor indicated in adult and paediatric patients aged one year and older with tuberous sclerosis complex for the treatment of subependymal giant cell astrocytoma
The group reported Q3FY25 operating revenue of Rs 3,821 crore, driven by sustained double-digit growth of 14 per cent in biosimilars
The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization
PAT after MI is Rs. 41 crore which is 162% increase
The revenue from operations in Q3 FY25 is Rs. 8,358.6 crore, up 16% YoY
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
Subscribe To Our Newsletter & Stay Updated
